cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.1568837.v1
title: Analysis of Driver Evasive Maneuvering Prior to Intersection Crashes Using Event Data Recorders

description: <b>Objective:</b> Intersection crashes account for over 4,500 fatalities in the United States each year. Intersection Advanced Driver Assistance Systems (I-ADAS) are emerging vehicle-based active safety systems that have the potential to help drivers safely navigate across intersections and prevent intersection crashes and injuries. The performance of an I-ADAS is expected to be highly dependent upon driver evasive maneuvering prior to an intersection crash. Little has been published, however, on the detailed evasive kinematics followed by drivers prior to real-world intersection crashes. The objective of this study was to characterize the frequency, timing, and kinematics of driver evasive maneuvers prior to intersection crashes.<b>Methods:</b> Event data recorders (EDRs) downloaded from vehicles involved in intersection crashes were investigated as part of NASS-CDS years 2001 to 2013. A total of 135 EDRs with precrash vehicle speed and braking application were downloaded to investigate evasive braking. A smaller subset of 59 EDRs that collected vehicle yaw rate was additionally analyzed to investigate evasive steering. Each vehicle was assigned to one of 3 precrash movement classifiers (traveling through the intersection, completely stopped, or rolling stop) based on the vehicle's calculated acceleration and observed velocity profile. To ensure that any significant steering input observed was an attempted evasive maneuver, the analysis excluded vehicles at intersections that were turning, driving on a curved road, or performing a lane change. Braking application at the last EDR-recorded time point was assumed to indicate evasive braking. A vehicle yaw rate greater than 4° per second was assumed to indicate an evasive steering maneuver.<b>Results:</b> Drivers executed crash avoidance maneuvers in four-fifths of intersection crashes. A more detailed analysis of evasive braking frequency by precrash maneuver revealed that drivers performing complete or rolling stops (61.3%) braked less often than drivers traveling through the intersection without yielding (79.0%). After accounting for uncertainty in the timing of braking and steering data, the median evasive braking time was found to be between 0.5 to 1.5 s prior to impact, and the median initial evasive steering time was found to occur between 0.5 and 0.9 s prior to impact. The median average evasive braking deceleration for all cases was found to be 0.58 g. The median of the maximum evasive vehicle yaw rates was found to be 8.2° per second. Evasive steering direction was found to be most frequently in the direction of travel of the approaching vehicle.<b>Conclusions:</b> The majority of drivers involved in intersection crashes were alert enough to perform an evasive action. Most drivers used a combination of steering and braking to avoid a crash. The average driver attempted to steer and brake at approximately the same time prior to the crash.
DOI: 10.6084/m9.figshare.1568822
title: Postoperative infections following colorectal surgery in an English teaching hospital

description: A retrospective case note review of postoperative infections within 30 days of colorectal surgery was completed. Surgical site infections (SSIs) were identified in 22% of patients (84/378), with other infections, e.g. urinary tract infections, identified in 18.3% of patients. SSIs, urinary and respiratory tract infections were all associated with increased durations of hospital admission compared with non-infected patients. Consideration should be given to postoperative surveillance for all infections, using antibiotic consumption as an objective outcome measure. Nine percent of patients developed an organ space SSI. Organ space SSIs were associated with the longest additional duration of hospital admission (15.5 days) and were the only infection associated with an increase in mortality at 1 year; 37% (13/35) mortality with an organ space SSI vs 4% (8/225) without an infection (odds ratio = 16, 95% confidence interval = 6, 43). Further research to prevent and treat organ space SSIs should be prioritized.
DOI: 10.6084/m9.figshare.1568822.v1
title: Postoperative infections following colorectal surgery in an English teaching hospital

description: A retrospective case note review of postoperative infections within 30 days of colorectal surgery was completed. Surgical site infections (SSIs) were identified in 22% of patients (84/378), with other infections, e.g. urinary tract infections, identified in 18.3% of patients. SSIs, urinary and respiratory tract infections were all associated with increased durations of hospital admission compared with non-infected patients. Consideration should be given to postoperative surveillance for all infections, using antibiotic consumption as an objective outcome measure. Nine percent of patients developed an organ space SSI. Organ space SSIs were associated with the longest additional duration of hospital admission (15.5 days) and were the only infection associated with an increase in mortality at 1 year; 37% (13/35) mortality with an organ space SSI vs 4% (8/225) without an infection (odds ratio = 16, 95% confidence interval = 6, 43). Further research to prevent and treat organ space SSIs should be prioritized.
DOI: 10.6084/m9.figshare.1568818
title: A Tale of Two Paralogs: Human Transformer2 proteins with differential RNA-binding affinities

description: The Transformer2 (Tra2) proteins in humans are homologues of the <i>Drosophila</i> Tra2 protein. One of the two RNA-binding paralogs, Tra2β, has been very well-studied over the past decade, but not much is known about Tra2α. It was very recently shown that the two proteins demonstrate the phenomenon of paralog compensation. Here, we provide a structural basis for this genetic backup circuit, using molecular modelling and dynamics studies. We show that the two proteins display similar binding specificities, but differential affinities to a short GAA-rich RNA stretch. Starting from the 6-nucleotide RNA in the solution structure, close to4000 virtual mutations were modelled on RNA and the domain-RNA interactionswere studied after energy minimization to convergence. Separately, anotherknown 13-nucleotide stretch was docked and the domain-RNA interactionswere observed through a 100-ns dynamics trajectory. We have also demonstrated the ‘compensatory’ mechanism at the level of domains in one of the domain repeat-containing RNA-binding proteins.
DOI: 10.6084/m9.figshare.1568818.v1
title: A Tale of Two Paralogs: Human Transformer2 proteins with differential RNA-binding affinities

description: The Transformer2 (Tra2) proteins in humans are homologues of the <i>Drosophila</i> Tra2 protein. One of the two RNA-binding paralogs, Tra2β, has been very well-studied over the past decade, but not much is known about Tra2α. It was very recently shown that the two proteins demonstrate the phenomenon of paralog compensation. Here, we provide a structural basis for this genetic backup circuit, using molecular modelling and dynamics studies. We show that the two proteins display similar binding specificities, but differential affinities to a short GAA-rich RNA stretch. Starting from the 6-nucleotide RNA in the solution structure, close to4000 virtual mutations were modelled on RNA and the domain-RNA interactionswere studied after energy minimization to convergence. Separately, anotherknown 13-nucleotide stretch was docked and the domain-RNA interactionswere observed through a 100-ns dynamics trajectory. We have also demonstrated the ‘compensatory’ mechanism at the level of domains in one of the domain repeat-containing RNA-binding proteins.
DOI: 10.6084/m9.figshare.1568822.v2
title: Postoperative infections following colorectal surgery in an English teaching hospital

description: A retrospective case note review of postoperative infections within 30 days of colorectal surgery was completed. Surgical site infections (SSIs) were identified in 22% of patients (84/378), with other infections, e.g. urinary tract infections, identified in 18.3% of patients. SSIs, urinary and respiratory tract infections were all associated with increased durations of hospital admission compared with non-infected patients. Consideration should be given to postoperative surveillance for all infections, using antibiotic consumption as an objective outcome measure. Nine percent of patients developed an organ space SSI. Organ space SSIs were associated with the longest additional duration of hospital admission (15.5 days) and were the only infection associated with an increase in mortality at 1 year; 37% (13/35) mortality with an organ space SSI vs 4% (8/225) without an infection (odds ratio = 16, 95% confidence interval = 6, 43). Further research to prevent and treat organ space SSIs should be prioritized.
DOI: 10.6084/m9.figshare.1568816
title: Phosphorylated ribosomal S6 (p-rpS6) as a post-treatment indicator of HER2 signalling targeted drug resistance

description: <i>Objective</i>: To identify clinically relevant predictive biomarkers of trastuzumab resistance.<i>Material and methods</i>: MTT, FACS assays, immunoblotting and immunocytochemistry were used to phenotypically characterize drug responses of two cell models BT474R and SKBR3R. Student's <i>t</i>-test and Spearman's correlation were applied for statistic analysis.<i>Results</i>: The activity of a downstream effector of the HER2 pathway phosphorylated ribosomal protein S6 (p-rpS6), was suppressed by trastuzumab in the parental cell lines yet remained unchanged in the resistant cells following treatment. The level of p-rpS6 was inversely correlated to the drug induced growth inhibition of trastuzumab-resistant cells when they are treated with selected HER2 targeting drugs.<i>Conclusion</i>: p-rpS6 is a robust post-treatment indicator of HER2 pathway-targeted therapy resistance.
DOI: 10.6084/m9.figshare.1568822.v4
title: Postoperative infections following colorectal surgery in an English teaching hospital

description: A retrospective case note review of postoperative infections within 30 days of colorectal surgery was completed. Surgical site infections (SSIs) were identified in 22% of patients (84/378), with other infections, e.g. urinary tract infections, identified in 18.3% of patients. SSIs, urinary and respiratory tract infections were all associated with increased durations of hospital admission compared with non-infected patients. Consideration should be given to postoperative surveillance for all infections, using antibiotic consumption as an objective outcome measure. Nine percent of patients developed an organ space SSI. Organ space SSIs were associated with the longest additional duration of hospital admission (15.5 days) and were the only infection associated with an increase in mortality at 1 year; 37% (13/35) mortality with an organ space SSI vs 4% (8/225) without an infection (odds ratio = 16, 95% confidence interval = 6, 43). Further research to prevent and treat organ space SSIs should be prioritized.
DOI: 10.6084/m9.figshare.1568816.v2
title: Phosphorylated ribosomal S6 (p-rpS6) as a post-treatment indicator of HER2 signalling targeted drug resistance

description: <i>Objective</i>: To identify clinically relevant predictive biomarkers of trastuzumab resistance.<i>Material and methods</i>: MTT, FACS assays, immunoblotting and immunocytochemistry were used to phenotypically characterize drug responses of two cell models BT474R and SKBR3R. Student's <i>t</i>-test and Spearman's correlation were applied for statistic analysis.<i>Results</i>: The activity of a downstream effector of the HER2 pathway phosphorylated ribosomal protein S6 (p-rpS6), was suppressed by trastuzumab in the parental cell lines yet remained unchanged in the resistant cells following treatment. The level of p-rpS6 was inversely correlated to the drug induced growth inhibition of trastuzumab-resistant cells when they are treated with selected HER2 targeting drugs.<i>Conclusion</i>: p-rpS6 is a robust post-treatment indicator of HER2 pathway-targeted therapy resistance.
DOI: 10.6084/m9.figshare.1568816.v1
title: Phosphorylated ribosomal S6 (p-rpS6) as a post-treatment indicator of HER2 signalling targeted drug resistance

description: <i>Objective</i>: To identify clinically relevant predictive biomarkers of trastuzumab resistance.<i>Material and methods</i>: MTT, FACS assays, immunoblotting and immunocytochemistry were used to phenotypically characterize drug responses of two cell models BT474R and SKBR3R. Student's <i>t</i>-test and Spearman's correlation were applied for statistic analysis.<i>Results</i>: The activity of a downstream effector of the HER2 pathway phosphorylated ribosomal protein S6 (p-rpS6), was suppressed by trastuzumab in the parental cell lines yet remained unchanged in the resistant cells following treatment. The level of p-rpS6 was inversely correlated to the drug induced growth inhibition of trastuzumab-resistant cells when they are treated with selected HER2 targeting drugs.<i>Conclusion</i>: p-rpS6 is a robust post-treatment indicator of HER2 pathway-targeted therapy resistance.
DOI: 10.6084/m9.figshare.1568822.v3
title: Postoperative infections following colorectal surgery in an English teaching hospital

description: A retrospective case note review of postoperative infections within 30 days of colorectal surgery was completed. Surgical site infections (SSIs) were identified in 22% of patients (84/378), with other infections, e.g. urinary tract infections, identified in 18.3% of patients. SSIs, urinary and respiratory tract infections were all associated with increased durations of hospital admission compared with non-infected patients. Consideration should be given to postoperative surveillance for all infections, using antibiotic consumption as an objective outcome measure. Nine percent of patients developed an organ space SSI. Organ space SSIs were associated with the longest additional duration of hospital admission (15.5 days) and were the only infection associated with an increase in mortality at 1 year; 37% (13/35) mortality with an organ space SSI vs 4% (8/225) without an infection (odds ratio = 16, 95% confidence interval = 6, 43). Further research to prevent and treat organ space SSIs should be prioritized.
DOI: 10.6084/m9.figshare.1568813
title: Identification of candidate biomarker mass (<i>m</i>/<i>z</i>) ranges in serous ovarian adenocarcinoma using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling

description: <i>Objective</i>: To differentiate plasma from ovarian cancer and healthy individuals using MALDI-TOF mass spectroscopy.<i>Materials and methods</i>: MALDI-TOF was used to generate profiles of immuno-depleted plasma samples (89 cancers and 199 healthy individuals) that were fractionated using three types of magnetic beads (HIC8, WCX and IMAC-Cu).<i>Results</i>: Differentially expressed mass ranges showing &gt;1.5–2-fold change in expression from HIC8 (30), WCX (12) and IMAC-Cu (6) fractions were identified. Cross validation and recognition capability scores for the models indicated discrimination between the classes.<i>Conclusions</i>: Spectral profiles can differentiate plasma samples of ovarian cancer patients from healthy individuals.
DOI: 10.6084/m9.figshare.1568811
title: Comparative efficacy of antibiotics for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a systematic review and network meta-analysis

description: Objective:The objective was to conduct a systematic review and network meta-analysis (NMA) of existing treatments for ABSSSI focusing on the novel lipoglycopeptide oritavancin.Methods:EMBASE, MEDLINE, MEDLINE in Process, CENTRAL (Cochrane), and select conferences were searched for randomized controlled trials investigating antimicrobial agents for the treatment of ABSSSI. NMA was used to estimate the odds ratios of the Test-Of-Cure (TOC) and Early Clinical Response (ECR) outcomes for treatments relative to vancomycin in the ITT populations. Sub-group analyses in MRSA and MSSA populations were conducted for TOC; sensitivity analyses investigated the use of the clinically evaluable (CE) populations and the restriction to trials following the recent FDA guidelines for clinical trials.Results:The systematic review identified 52 trials. The most commonly investigated treatments were vancomycin and linezolid; most trials reported TOC, but not ECR. The posterior mean and 95% credible intervals for odds ratios of TOC for antimicrobial agents relative to vancomycin were: linezolid (1.55; 0.91–2.57), daptomycin (2.18; 0.90–5.42), and oritavancin 1200 mg (1.06; 0.80–1.43). The odds ratio of ECR for oritavancin 1200 mg was 1.02 (0.23–4.33). In the MRSA sub-group the odds ratios relative to vancomycin for TOC were: linezolid (1.55; 0.96–2.46), daptomycin (0.74; 0.13–3.66), and oritavancin 1200 mg (0.94; 0.44–2.02). In the MSSA sub-group they were linezolid (1.36; 0.15–13.34) and oritavancin 1200 mg (0.82; 0.08–7.83). These results were robust to the sensitivity analyses.Conclusions:This NMA provides a unified framework for the comparison of all available antimicrobial agents used in the treatment of ABSSSI and is the first to assess the ECR end-point. The results suggest equivalence of clinical efficacy between vancomycin, daptomycin, linezolid, and novel antimicrobial agents including oritavancin for the treatment of ABSSSI at TOC. The wide uncertainty margins indicate the heterogeneity of the available evidence and the need for further research.
DOI: 10.6084/m9.figshare.1568813.v2
title: Identification of candidate biomarker mass (<i>m</i>/<i>z</i>) ranges in serous ovarian adenocarcinoma using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling

description: <i>Objective</i>: To differentiate plasma from ovarian cancer and healthy individuals using MALDI-TOF mass spectroscopy.<i>Materials and methods</i>: MALDI-TOF was used to generate profiles of immuno-depleted plasma samples (89 cancers and 199 healthy individuals) that were fractionated using three types of magnetic beads (HIC8, WCX and IMAC-Cu).<i>Results</i>: Differentially expressed mass ranges showing &gt;1.5–2-fold change in expression from HIC8 (30), WCX (12) and IMAC-Cu (6) fractions were identified. Cross validation and recognition capability scores for the models indicated discrimination between the classes.<i>Conclusions</i>: Spectral profiles can differentiate plasma samples of ovarian cancer patients from healthy individuals.
DOI: 10.6084/m9.figshare.1568813.v1
title: Identification of candidate biomarker mass (<i>m</i>/<i>z</i>) ranges in serous ovarian adenocarcinoma using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling

description: <i>Objective</i>: To differentiate plasma from ovarian cancer and healthy individuals using MALDI-TOF mass spectroscopy.<i>Materials and methods</i>: MALDI-TOF was used to generate profiles of immuno-depleted plasma samples (89 cancers and 199 healthy individuals) that were fractionated using three types of magnetic beads (HIC8, WCX and IMAC-Cu).<i>Results</i>: Differentially expressed mass ranges showing &gt;1.5–2-fold change in expression from HIC8 (30), WCX (12) and IMAC-Cu (6) fractions were identified. Cross validation and recognition capability scores for the models indicated discrimination between the classes.<i>Conclusions</i>: Spectral profiles can differentiate plasma samples of ovarian cancer patients from healthy individuals.
DOI: 10.6084/m9.figshare.1568811.v1
title: Comparative efficacy of antibiotics for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a systematic review and network meta-analysis

description: Objective:The objective was to conduct a systematic review and network meta-analysis (NMA) of existing treatments for ABSSSI focusing on the novel lipoglycopeptide oritavancin.Methods:EMBASE, MEDLINE, MEDLINE in Process, CENTRAL (Cochrane), and select conferences were searched for randomized controlled trials investigating antimicrobial agents for the treatment of ABSSSI. NMA was used to estimate the odds ratios of the Test-Of-Cure (TOC) and Early Clinical Response (ECR) outcomes for treatments relative to vancomycin in the ITT populations. Sub-group analyses in MRSA and MSSA populations were conducted for TOC; sensitivity analyses investigated the use of the clinically evaluable (CE) populations and the restriction to trials following the recent FDA guidelines for clinical trials.Results:The systematic review identified 52 trials. The most commonly investigated treatments were vancomycin and linezolid; most trials reported TOC, but not ECR. The posterior mean and 95% credible intervals for odds ratios of TOC for antimicrobial agents relative to vancomycin were: linezolid (1.55; 0.91–2.57), daptomycin (2.18; 0.90–5.42), and oritavancin 1200 mg (1.06; 0.80–1.43). The odds ratio of ECR for oritavancin 1200 mg was 1.02 (0.23–4.33). In the MRSA sub-group the odds ratios relative to vancomycin for TOC were: linezolid (1.55; 0.96–2.46), daptomycin (0.74; 0.13–3.66), and oritavancin 1200 mg (0.94; 0.44–2.02). In the MSSA sub-group they were linezolid (1.36; 0.15–13.34) and oritavancin 1200 mg (0.82; 0.08–7.83). These results were robust to the sensitivity analyses.Conclusions:This NMA provides a unified framework for the comparison of all available antimicrobial agents used in the treatment of ABSSSI and is the first to assess the ECR end-point. The results suggest equivalence of clinical efficacy between vancomycin, daptomycin, linezolid, and novel antimicrobial agents including oritavancin for the treatment of ABSSSI at TOC. The wide uncertainty margins indicate the heterogeneity of the available evidence and the need for further research.
DOI: 10.6084/m9.figshare.1568811.v3
title: Comparative efficacy of antibiotics for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a systematic review and network meta-analysis

description: Objective:The objective was to conduct a systematic review and network meta-analysis (NMA) of existing treatments for ABSSSI focusing on the novel lipoglycopeptide oritavancin.Methods:EMBASE, MEDLINE, MEDLINE in Process, CENTRAL (Cochrane), and select conferences were searched for randomized controlled trials investigating antimicrobial agents for the treatment of ABSSSI. NMA was used to estimate the odds ratios of the Test-Of-Cure (TOC) and Early Clinical Response (ECR) outcomes for treatments relative to vancomycin in the ITT populations. Sub-group analyses in MRSA and MSSA populations were conducted for TOC; sensitivity analyses investigated the use of the clinically evaluable (CE) populations and the restriction to trials following the recent FDA guidelines for clinical trials.Results:The systematic review identified 52 trials. The most commonly investigated treatments were vancomycin and linezolid; most trials reported TOC, but not ECR. The posterior mean and 95% credible intervals for odds ratios of TOC for antimicrobial agents relative to vancomycin were: linezolid (1.55; 0.91–2.57), daptomycin (2.18; 0.90–5.42), and oritavancin 1200 mg (1.06; 0.80–1.43). The odds ratio of ECR for oritavancin 1200 mg was 1.02 (0.23–4.33). In the MRSA sub-group the odds ratios relative to vancomycin for TOC were: linezolid (1.55; 0.96–2.46), daptomycin (0.74; 0.13–3.66), and oritavancin 1200 mg (0.94; 0.44–2.02). In the MSSA sub-group they were linezolid (1.36; 0.15–13.34) and oritavancin 1200 mg (0.82; 0.08–7.83). These results were robust to the sensitivity analyses.Conclusions:This NMA provides a unified framework for the comparison of all available antimicrobial agents used in the treatment of ABSSSI and is the first to assess the ECR end-point. The results suggest equivalence of clinical efficacy between vancomycin, daptomycin, linezolid, and novel antimicrobial agents including oritavancin for the treatment of ABSSSI at TOC. The wide uncertainty margins indicate the heterogeneity of the available evidence and the need for further research.